Determining in vitro synergistic activities of tigecycline with several other antibiotics against Brucella melitensis using checkerboard and time-kill assays

Journal of Chemotherapy

Volumn 21, Issue 1, 2009, Pages 24-30

  Alişkan, Hikmet ^a   Can, F ^a   Demirbilek, M ^a   Çolakoǧlu, Ş ^a   Kilic S ^b   Arslan, H ^a  

^a BASKENT UNIVERSITY   (Turkey)

^b Parasitology Laboratory   (Turkey)

Author keywords

Brucellosis; Checkerboard; Synergy; Tigecycline; Time kill

Indexed keywords

ANTIBIOTIC AGENT; COTRIMOXAZOLE; GENTAMICIN; LEVOFLOXACIN; MINOCYCLINE; RIFAMPICIN; STREPTOMYCIN; TIGECYCLINE;

ANALYTICAL PARAMETERS; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BRUCELLA MELITENSIS; BRUCELLOSIS; CHECKERBOARD METHOD; COLONY FORMING UNIT; CONTROLLED STUDY; CULTURE MEDIUM; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TIME KILL ASSAY;

EID: 63049124732     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.1.24     Document Type: Article

References (28)

1. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect Dis 2006; 6: 91-9.
2. Health Ministry of Turkish Republic, Basic Health Service Annual Report of 2004.
3. Young EJ, Brucella species. In: Mandell GL, Bennett JE, eds. Principles and Practice of Infectious Diseases. 5th ed. New York: Churchill Livingstone, 2000: 2386-93.
4. Pappas G, Solera J, Akritidis N, Tsianos E. New approaches to the antibiotic treatment of brucellosis. Int J Antimicrob Agents 2005; 26: 101-5.
5. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005 1; 41 Suppl 5: 03-314.
6. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureoplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 2001; 45: 2604-8.
7. Wallace RJ Jr, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycydine against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46: 3164-7.
8. Corbel MJ. Microbiological aspects. In: Madkour MM, ed. Madkour's brucellosis. 2th ed. Berlin Heidelberg New York: Springer-Verlag. 2001: 51-64.
9. Alton GG, Jones LM, Angus RD, Verger JM. Techniques for the brucellosis Laboratory. Paris: Institut National de la recherche Agronomique (INRA). 1988: 34-61.
10. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement M100-S16. CLSI, Wayne, PA, USA, 2006.
11. Orhan G, Bayram A, Zer Y, Balci I. Synergy tests by E-test and checkerboard methods of antimicrobial combinations against Brucella melitensis. J Clin Microbiol 2005; 43: 140-3.
12. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52:1.
13. Rubinstein E, Lang R, Shasha B et al. In vitro susceptibility of Brucella melitensis to antibiotics. Antimicrob Agents Chemother 1991; 35: 1925-7.
14. Petersen PJ, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton broth. Diagn Microbiol Infect Dis 2007; 59: 347-9.
15. Allen GP, Cha R, Rybak MJ. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2002; 46: 2606-12.
16. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/ pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005; 52: 165-71.
17. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58: 1221-9.
18. Ong CT, Babalola CP, Nightingale CH, Nicalou DP. Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J Antimicrob Chemother 2005; 56: 498-501.
19. Dizbay M, Kilic S, Hizel K, Arman D. Tigecycline: its potential for treatment of brucellosis. Scand J Infect Dis 2007; 39: 432-4.
20. Turan H, Arslan H, Azap OK, Serefhanoglu K, Uncu H. In vitro antibacterial activity of tigecycline in comparison with doxycydine, ciprofloxacin and rifampicin against Brucella spp. Int J Antimicrob Agents 2007; 30: 186-7.
21. Kilic D, Dizbay M, Cabadak H. In vitro activity of tigecycline, tetracycline and fluoroquinolones against Brucella melitensis. J Chemother 2008; 20: 33-7.
22. White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother 1996; 40: 1914-8.
23. Pappas G, Seitaridis S, Akritidis N, Tsianos E. Treatment of brucella spondylitis: lessons from an impossible meta-analysis and initial report of efficacy of a fluoroquinolone-containing regimen. Int J Antimicrob Agents 2004; 24: 502-7.
24. Arda B, Tuncel M, Yaimazhan T, Gökengin D, Gürel O. Efficacy of oral levofloxacin and dirithromycin alone in combination with rifampicin in the treatment of experimental murine Brucella abortus infection. Int J Antimicrob Agents 2004; 23: 204-7.
25. Solera J, Espinosa A, Martinez-Alfaro E, et al. Treatment of human brucellosis with doxycycline and gentamicin. Antimicrob agents Chemother 1997; 41: 80-1.
26. Ariza J, Bosilkovski M, Cascio A, et al. Perspectives for the treatment of brucellosis in the 21st century: The Ioannina recommendations. PLoS Med 2007; 12: 317.
27. Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 2006; 57: 573-6.
28. Chandrasekar PH, Crane LR, Bailey EJ. Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients. J Antimicrob Chemother 1987; 19: 321-9.